New Alzheimer’s research from UVA Health suggests that enhanced light sensitivity may contribute to “sundowning” – the worsening of symptoms late in the day – and spur sleep disruptions thought to contribute to the disease’s progression.
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership – Pharmaceutical Technology
Quell’s Treg platform induces sustained expression of FOXP3. Image credit: Shutterstock/ Vink Fan. AstraZeneca has exercised an option to license a cell therapy from Quell